Related Experiment Video
Updated: Feb 6, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma
Mingxiao Lang1, Jingwei Yu1, Xianhuo Wang1
1National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Sino-US Center for Lymphoma and Leukemia, Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Insights
An increase in absolute monocyte count (AMC) during immunochemotherapy may predict interstitial pneumonia (IP) in lymphoma patients. Monitoring AMC changes can help identify patients at risk for IP and guide treatment adjustments.
Area of Science:
- Oncology
- Pulmonology
- Hematology
Background:
- Interstitial pneumonia (IP) is a serious adverse event in lymphoma patients receiving immunochemotherapy.
- Risk factors and predictive markers for IP remain poorly understood.
- Absolute monocyte count (AMC) changes during treatment may be linked to IP development.
Purpose of the Study:
- To investigate the correlation between changes in absolute monocyte count (AMC) and the occurrence and progression of interstitial pneumonia (IP) in lymphoma patients undergoing immunochemotherapy.
- To identify potential predictive markers for IP in this patient population.
Main Methods:
- Retrospective study of 500 lymphoma patients treated with immunochemotherapy between 2014 and 2016.
- Diagnosis of IP based on computed tomography (CT) scans, respiratory symptoms, and pulmonary function tests.
- Analysis of peripheral AMC levels at different time points during chemotherapy, including multivariate analysis to identify independent risk factors.
Main Results:
- 40 out of 500 patients (8%) developed IP, with a median of 4 chemotherapy cycles prior to diagnosis.
- An increase in peripheral AMC over 0.565 × 10^9 /L after 2 cycles of immunochemotherapy was associated with a higher risk of developing IP.
- Lymphoma lung involvement and elevated AMC after 2 cycles were identified as independent risk factors for IP.
- Sustained AMC elevation (>0.575 × 10^9 /L) at IP onset correlated with severe pulmonary symptoms, while AMC decrease suggested better tolerance to treatment.
Conclusions:
- Early increase in absolute monocyte count (AMC) during immunochemotherapy in lymphoma patients, particularly those with lung involvement, is a significant potential predictor of interstitial pneumonia (IP).
- Dynamic monitoring of AMC may serve as a valuable biomarker for predicting IP severity and guiding treatment adjustments for both the malignancy and pulmonary complications.
Abstract:
Interstitial pneumonia (IP) is one of the potentially fatal adverse events for lymphoma patients undergoing immunochemotherapy. However, the risk factors and predictive markers remain unclear for this complication. This retrospective study aims to explore whether the change of absolute monocyte count (AMC) during immunochemotherapy is correlated with IP occurrence and progression. A total of 500 lymphoma patients receiving immunochemotherapy from 2014 to 2016 were enrolled in this investigation. Interstitial pneumonia was generally diagnosed as diffused pulmonary interstitial infiltrates on computed tomography images in conjunction with respiratory symptoms or pulmonary function test, which is also adopted as a diagnosing tool of IP in this study. Among the total 500 participating patients, 40 patients were diagnosed as IP, which account for 8% of the total subjects. The median number of chemotherapy cycles for those patients prior to IP occurrence is 4. This research suggests that the increase of peripheral AMC over 0.565 × 109 /L after 2 cycles of immunochemotherapy is a great potential to develop IP. Using the method of multivariate analysis, lymphoma lung involvement and high AMC after 2 cycles of immunochemotherapy were identified as independent risk factors for IP. Most IP patients with sustained AMC elevation (>0.575 × 109 /L at IP onset) accompanied severe pulmonary symptoms, while those with AMC fall-back might tolerate subsequent immunochemotherapy. Thus, this study concludes that early increase of AMC during immunochemotherapy in lymphoma patients with lung involvement suggested a great potential to develop IP. Dynamic changes in AMC may serve as a predictive marker for IP severity and a guide for treatment adjustment for both tumor and pulmonary injuries.
More Related Videos
Related Concept Videos
Predicting Molecular Geometry
Absolute Value Inequalities
Mean Absolute Deviation
Let us consider a dataset containing the number of unsold cupcakes in five shops: 10, 15, 8, 7, and 10. Initially, calculate the sample mean. Then calculate the deviation, or the difference, between each data value and the mean. Next, the absolute values of these deviations are added and divided by the sample size to...
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Increasing Function

